Muscle Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major muscle spasticity markets reached a value of US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6.9 Billion by 2034, exhibiting a growth rate (CAGR) of 6.84% during 2024-2034.
The muscle spasticity market has been comprehensively analyzed in IMARC's new report titled "Muscle Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Muscle spasticity refers to a condition characterized by involuntary and sustained muscle contractions or spasms. It is a common symptom observed in various neurological disorders that impact the central nervous system, such as multiple sclerosis, spinal cord injury, cerebral palsy, etc. Some of the indications associated with the ailment include involuntary muscle contractions, muscle stiffness and tightness, increased muscle tone, exaggerated reflexes, muscle and joint pain, difficulty with coordinated movements, limited range of motion, etc. These symptoms can vary in intensity and affect different muscle groups, leading to challenges in mobility, posture, and performing activities of daily living. The diagnosis of muscle spasticity involves a comprehensive evaluation by a healthcare professional, typically a neurologist or a physiatrist specializing in rehabilitation medicine. The diagnostic process includes a thorough medical history review, a physical examination to assess muscle tone and reflexes, and neurological tests to check motor function as well as identify any underlying conditions contributing to the condition. Various additional diagnostic tools, such as electromyography (EMG), nerve conduction studies, imaging scans, etc., are also utilized to further evaluate the extent and cause of muscle spasticity.
The increasing cases of stroke that result in brain cell damage as well as disruption of motor control and nerve signaling are primarily driving the muscle spasticity market. In addition to this, the growing prevalence of spinal cord injuries, which can lead to uncontrolled or exaggerated signals to the muscles and loss of inhibitory control, is also creating a positive outlook for the market. Moreover, the widespread adoption of various oral medications, such as baclofen, tizanidine, dantrolene sodium, etc., since they assist in reducing nerve signals that cause muscle contractions, is further bolstering the market growth. Apart from this, the emerging popularity of botulinum toxin injections on account of their several associated benefits, including decreased muscle contractures, improved range of motion, and enhanced functionality, is acting as another significant growth-inducing factor. Additionally, the inflating demand for numerous electrical stimulation techniques, such as functional electrical stimulation (FES) and transcutaneous electrical nerve stimulation (TENS), which deliver controlled electrical impulses to specific muscles, thereby promoting relaxation, is expected to drive the muscle spasticity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the muscle spasticity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for muscle spasticity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the muscle spasticity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the muscle spasticity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the muscle spasticity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current muscle spasticity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the muscle spasticity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the muscle spasticity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the muscle spasticity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of muscle spasticity across the seven major markets?
What is the number of prevalent cases (2018-2034) of muscle spasticity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of muscle spasticity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with muscle spasticity across the seven major markets?
What is the size of the muscle spasticity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of muscle spasticity?
What will be the growth rate of patients across the seven major markets?
Muscle Spasticity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for muscle spasticity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the muscle spasticity market?
What are the key regulatory events related to the muscle spasticity market?
What is the structure of clinical trial landscape by status related to the muscle spasticity market?
What is the structure of clinical trial landscape by phase related to the muscle spasticity market?
What is the structure of clinical trial landscape by route of administration related to the muscle spasticity market?
The muscle spasticity market has been comprehensively analyzed in IMARC's new report titled "Muscle Spasticity Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Muscle spasticity refers to a condition characterized by involuntary and sustained muscle contractions or spasms. It is a common symptom observed in various neurological disorders that impact the central nervous system, such as multiple sclerosis, spinal cord injury, cerebral palsy, etc. Some of the indications associated with the ailment include involuntary muscle contractions, muscle stiffness and tightness, increased muscle tone, exaggerated reflexes, muscle and joint pain, difficulty with coordinated movements, limited range of motion, etc. These symptoms can vary in intensity and affect different muscle groups, leading to challenges in mobility, posture, and performing activities of daily living. The diagnosis of muscle spasticity involves a comprehensive evaluation by a healthcare professional, typically a neurologist or a physiatrist specializing in rehabilitation medicine. The diagnostic process includes a thorough medical history review, a physical examination to assess muscle tone and reflexes, and neurological tests to check motor function as well as identify any underlying conditions contributing to the condition. Various additional diagnostic tools, such as electromyography (EMG), nerve conduction studies, imaging scans, etc., are also utilized to further evaluate the extent and cause of muscle spasticity.
The increasing cases of stroke that result in brain cell damage as well as disruption of motor control and nerve signaling are primarily driving the muscle spasticity market. In addition to this, the growing prevalence of spinal cord injuries, which can lead to uncontrolled or exaggerated signals to the muscles and loss of inhibitory control, is also creating a positive outlook for the market. Moreover, the widespread adoption of various oral medications, such as baclofen, tizanidine, dantrolene sodium, etc., since they assist in reducing nerve signals that cause muscle contractions, is further bolstering the market growth. Apart from this, the emerging popularity of botulinum toxin injections on account of their several associated benefits, including decreased muscle contractures, improved range of motion, and enhanced functionality, is acting as another significant growth-inducing factor. Additionally, the inflating demand for numerous electrical stimulation techniques, such as functional electrical stimulation (FES) and transcutaneous electrical nerve stimulation (TENS), which deliver controlled electrical impulses to specific muscles, thereby promoting relaxation, is expected to drive the muscle spasticity market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the muscle spasticity market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for muscle spasticity and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the muscle spasticity market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the muscle spasticity market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the muscle spasticity market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current muscle spasticity marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the muscle spasticity market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the muscle spasticity market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the muscle spasticity market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of muscle spasticity across the seven major markets?
What is the number of prevalent cases (2018-2034) of muscle spasticity by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of muscle spasticity by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with muscle spasticity across the seven major markets?
What is the size of the muscle spasticity patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of muscle spasticity?
What will be the growth rate of patients across the seven major markets?
Muscle Spasticity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for muscle spasticity drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the muscle spasticity market?
What are the key regulatory events related to the muscle spasticity market?
What is the structure of clinical trial landscape by status related to the muscle spasticity market?
What is the structure of clinical trial landscape by phase related to the muscle spasticity market?
What is the structure of clinical trial landscape by route of administration related to the muscle spasticity market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MUSCLE SPASTICITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MUSCLE SPASTICITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MUSCLE SPASTICITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MUSCLE SPASTICITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MUSCLE SPASTICITY - UNMET NEEDS
10 MUSCLE SPASTICITY - KEY ENDPOINTS OF TREATMENT
11 MUSCLE SPASTICITY - MARKETED PRODUCTS
11.1 List of Muscle Spasticity Marketed Drugs Across the Top 7 Markets
11.1.1 Fleqsuvy (Baclofen Oral Suspension) - Azurity Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zanaflex (Tizanidine Hydrochloride) - Acorda Therapeutics Inc
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Xeomin (Incobotulinumtoxina) - Merz Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dysport (Abobotulinumtoxina) - Ipsen
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Valium (Diazepam) - Genentech
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MUSCLE SPASTICITY - PIPELINE DRUGS
12.1 List of Muscle Spasticity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MUSCLE SPASTICITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MUSCLE SPASTICITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MUSCLE SPASTICITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Muscle Spasticity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Muscle Spasticity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Muscle Spasticity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Muscle Spasticity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Muscle Spasticity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Muscle Spasticity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Muscle Spasticity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Muscle Spasticity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Muscle Spasticity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Muscle Spasticity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Muscle Spasticity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Muscle Spasticity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Muscle Spasticity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Muscle Spasticity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Muscle Spasticity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Muscle Spasticity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Muscle Spasticity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Muscle Spasticity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Muscle Spasticity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Muscle Spasticity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Muscle Spasticity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Muscle Spasticity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Muscle Spasticity - Access and Reimbursement Overview
16 MUSCLE SPASTICITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MUSCLE SPASTICITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MUSCLE SPASTICITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MUSCLE SPASTICITY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MUSCLE SPASTICITY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MUSCLE SPASTICITY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MUSCLE SPASTICITY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MUSCLE SPASTICITY - UNMET NEEDS
10 MUSCLE SPASTICITY - KEY ENDPOINTS OF TREATMENT
11 MUSCLE SPASTICITY - MARKETED PRODUCTS
11.1 List of Muscle Spasticity Marketed Drugs Across the Top 7 Markets
11.1.1 Fleqsuvy (Baclofen Oral Suspension) - Azurity Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zanaflex (Tizanidine Hydrochloride) - Acorda Therapeutics Inc
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Xeomin (Incobotulinumtoxina) - Merz Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dysport (Abobotulinumtoxina) - Ipsen
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Valium (Diazepam) - Genentech
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MUSCLE SPASTICITY - PIPELINE DRUGS
12.1 List of Muscle Spasticity Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MUSCLE SPASTICITY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MUSCLE SPASTICITY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MUSCLE SPASTICITY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Muscle Spasticity - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Muscle Spasticity - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Muscle Spasticity - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Muscle Spasticity - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Muscle Spasticity - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Muscle Spasticity - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Muscle Spasticity - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Muscle Spasticity - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Muscle Spasticity - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Muscle Spasticity - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Muscle Spasticity - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Muscle Spasticity - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Muscle Spasticity - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Muscle Spasticity - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Muscle Spasticity - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Muscle Spasticity - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Muscle Spasticity - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Muscle Spasticity - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Muscle Spasticity - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Muscle Spasticity - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Muscle Spasticity - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Muscle Spasticity - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Muscle Spasticity - Access and Reimbursement Overview
16 MUSCLE SPASTICITY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MUSCLE SPASTICITY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MUSCLE SPASTICITY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
